Evidence Explorer · MS-N235 · Traditional Chinese herbal tea · Supportive care · Appraised November 4, 2026
A 19-person randomized study did not show a specific between-group fatigue or quality-of-life benefit. Improvement within both groups cannot be attributed to the tea.
Evidence at a glance
Benefit signal: No demonstrated between-group fatigue benefit
Certainty: Very low; tiny crossover-style study with 19 analyzed participants
Risk context: Composition, interaction and adverse-event reporting are insufficient for broad safety conclusions
What was studied
Twenty-one people with gynecologic cancer and moderate-to-severe fatigue were enrolled; 19 were analyzed. Jing Si herbal tea 15 mL twice daily was given for six weeks. The control group received placebo for three weeks and then crossed to the tea for three weeks.
There was no statistically significant between-group difference in Brief Fatigue Inventory–Taiwan or FACT-G7 quality-of-life improvement. Both groups improved, and a monocyte-count difference was exploratory.
What this evidence cannot establish
The sample was far too small to exclude meaningful benefit or harm. Within-group change, monocyte counts and laboratory observations do not prove clinical efficacy.
The trial did not establish tumor control, and the 2026 systematic review rated all included herbal-preparation outcomes very low certainty.
Practical safety context
Short follow-up and incomplete adverse-event reporting cannot establish safety. The exact multi-ingredient product and its interaction profile must be reviewed rather than inferred from the word “tea.”
Fatigue during treatment warrants assessment for anemia, infection, endocrine dysfunction, sleep problems, medication effects and disease progression.
Questions for the care team
- What are all ingredients and concentrations in the proposed product?
- Could any component interact with chemotherapy, anticoagulants or liver metabolism?
- Is there a reversible medical cause for the fatigue?
- Would exercise, sleep or psychosocial interventions with stronger evidence fit this situation?
Funding and conflicts
The authors reported no conflicts of interest. Funding and manufacturer involvement were not fully verified from the accessible report.
Sources
- Randomized trial (PMID 41189208)
- 2026 systematic review of oral herbal preparations in supportive cancer care (PMID 42930516)
Sources and publication status checked November 4, 2026. Last literature search: November 4, 2026; record appraisal: November 4, 2026.
For education, not personal medical advice. Research regimens are not personal prescriptions. Symptom, laboratory or biomarker changes do not establish tumor response, recurrence prevention or longer survival.
